Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment
By Ben Glickman
Sobi North America said it had received fast track designation from U.S. regulators for its potential treatment for Macrophage Activation Syndrome, a complication of rheumatic diseases.
The Waltham, Mass.-based affiliate of Swedish Orphan Biovitrum said Friday that the U.S. Food and Drug Administration had granted the designation to emapalumab-lzsg, a monoclonal antibody. The compound is currently the only medicine approved in the U.S. for primary haemophagocytic lymphohistiocytosis, a syndrome of hyperinflammation also known as HLH, according to Sobi.
MAS, a form of HLH, is characterized by fever, liver dysfunction and other symptoms.
Emapalumab is currently in phase 3 development for treating MAS.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 24, 2024 15:45 ET (19:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase